Document:

<PAGE>   1
                                                                   EXHIBIT 10.33

                        STRATEGIC RELATIONSHIP AGREEMENT

         THIS STRATEGIC RELATIONSHIP AGREEMENT (this "Agreement") is entered
into as of January 7, 2000, by and among MEDIBUY.COM, INC., a Delaware
corporation having its principal place of business at 10120 Pacific Heights
Boulevard, Suite 100, San Diego, California 92121 (the "Company"), Allianz
Capital Partners, GmbH, and Jochen Noelke (each a "Strategic Partner" and
together the "Strategic Partners").

                                    RECITALS

         WHEREAS, the Company is in the business of providing web-based commerce
and content applications for the global healthcare community of buyers and
vendors (the "Business"), and desires to take steps to explore and potentially
expand the Business to include Europe; and

         WHEREAS, each of the Strategic Partners severally has information,
knowledge and relationships which may be of assistance to the Company in
pursuing such expansion of the Business, which information, knowledge and
relationships the Company desires to obtain from the Strategic Partners and the
Strategic Partners desire to make available to the Company on the terms and
conditions set forth below.

         NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual promises hereinafter set forth, the parties agree as follows:

         1. INFORMATION. Each of the Strategic Partners hereby severally agrees
that, from time to time during the "Term" (as defined below) upon the request of
the Company, each Strategic Partner shall use good faith efforts to provide the
Company on a timely basis with information and know-how concerning (i) European
health care markets generally, (ii) distribution channels for the sale of health
care related products in European markets, (iii) competitive enterprises in the
European markets as they are identified by the Company or either Strategic
Partner, (iv) practice and custom concerning the distribution and sale of health
care products in European markets, and (v) identification of, and introduction
to, additional sources of information regarding European markets. In addition,
during the Term and upon the request of the Company, each Strategic Partner
shall use good faith efforts to provide the Company on timely basis with
introductions to persons or entities which may be beneficial to the Company in
the European expansion of the Business.

         The Company acknowledges that neither Strategic Partner makes any
representations or warranties regarding (i) the accuracy or completeness of any
information provided to the Company, (ii) the value of such information, or
(iii) any outcome or expected benefit to the Company from the use of such
information. The Company also acknowledges that neither Strategic Party shall be
obligated to provide any information if, in the reasonable opinion of such
Strategic Partner, the provision of such information would violate applicable
laws, rules or regulations, or any contract binding on such Strategic Partner
restricting the use or disclosure of such information. Each Strategic Partner
hereby disclaims any and all warranties concerning any information provided to
the Company.

<PAGE>   2

         2. TERM. This Agreement shall commence on the date hereof and shall
terminate on the first anniversary hereof unless extended by the mutual written
agreement of the parties. The Company may terminate this Agreement at any time
with regard to a Strategic Partner upon delivery of written notice to such
Strategic Partner.

         3.       MISCELLANEOUS.

                  3.1 SUCCESSORS AND ASSIGNS. Except as otherwise expressly
provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors and administrators of
the parties hereto and shall inure to the benefit of and be enforceable by each
person who shall be a holder of the Shares from time to time. This Agreement and
the obligations hereunder may not be assigned without the prior written consent
of all of the parties.

                  3.2 ENTIRE AGREEMENT. This Agreement constitutes the full and
entire understanding and agreement between the parties with regard to the
subjects hereof and no party shall be liable or bound to any other in any manner
by any representations, warranties, covenants and agreements except as
specifically set forth herein and therein.

                  3.3 SEVERABILITY. In case any provision of the Agreement shall
be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired
thereby.

                  3.4 AMENDMENT AND WAIVER. This Agreement may be amended or
modified only upon the written consent of the Company and the Strategic
Partners. The obligations and the rights of the parties under the Agreement may
be waived only with the written consent of the party from whom such waiver is
sought.

                  3.5 NOTICES. All notices required or permitted hereunder shall
be in writing and shall be deemed effectively given: (a) upon personal delivery
to the party to be notified, (b) when sent by confirmed telex or facsimile if
sent during normal business hours of the recipient, if not, then on the next
business day, (c) ten (10) days after having been sent by registered or
certified mail, return receipt requested, postage prepaid, or (d) four (4)
business days after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All
communications shall be sent to the parties at the addresses for such parties on
the books and records of the parties or at such other address as the any party
may desire to designate by ten (10) days advance written notice to the other
parties hereto.

                  3.6 EXPENSES. Each party shall bear its own expenses in the
negotiation, execution and performance of this Agreement.

                  3.7 TITLES AND SUBTITLES. The titles of the sections and
subsections of the Agreement are for convenience of reference only and are not
to be considered in construing this Agreement.

<PAGE>   3

                  3.8 COUNTERPARTS. This Agreement may be executed in any number
of counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.

                  3.9 CONFIDENTIALITY. Each Strategic Partner and the Company
severally agrees that, except with the prior written consent of the party from
whom such information was obtained, it shall at all times keep confidential and
not divulge, furnish or make accessible to any third party any confidential
information, knowledge or data concerning or relating to the Business or
provided by a Strategic Partner pursuant to Section 1 above; provided, however,
that no party shall be under such obligation with respect to any information,
knowledge or data which (i) becomes publicly known and made generally available
through no wrongful act of such party or (ii) is publicly known and generally
available in the public domain prior to the time of disclosure.

         3.10 PRONOUNS. All pronouns contained herein, and any variations
thereof, shall be deemed to refer to the masculine, feminine or neutral,
singular or plural, as to the identity of the parties hereto may require.

         3.11 GOVERNING LAW. This Agreement shall be governed in all respects by
the laws of the State of California as such laws are applied to agreements
between California residents entered into and performed entirely in California.

                      [THIS SPACE INTENTIONALLY LEFT BLANK]

<PAGE>   4

         IN WITNESS WHEREOF, the parties hereto have executed this Strategic
Relationship Agreement as of the date first set forth above.

                         COMPANY:

                         MEDIBUY.COM, INC.

                         By: /S/ NORMAN FARQUHAR
                            -------------------------------
                         Name:   Norman Farquhar
                              -----------------------------
                         Title:  EVP & CFO
                               ----------------------------

                         STRATEGIC PARTNERS:

                         ALLIANZ CAPITAL PARTNERS, GMBH

                         By: /S/ THOMAS PUTTER   /S/ MARTIN ARNOLD
                            -------------------------------
                         Name: Thomas Putter         Martin Arnold
                              -----------------------------
                         Title:   CEO             Sen. Inv. Manager
                               ----------------------------

                         JOCHEN NOELKE

                           /S/ JOCHEN NOELKE
                         -----------------------------------<PAGE>   1
                                                                   EXHIBIT 10.34

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE
EFFECTED WITHOUT (I) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (II)
AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY,
THAT SUCH REGISTRATION IS NOT REQUIRED, (III) RECEIPT OF NO-ACTION LETTERS FROM
THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (IV) OTHERWISE COMPLYING WITH THE
PROVISIONS OF SECTION 7 OF THIS WARRANT.

THIS WARRANT HAS BEEN ACQUIRED PURSUANT TO REGULATION S OF THE ACT, AND MAY NOT
BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN
ACCORDANCE WITH REGULATION S, PURSUANT TO A REGISTRATION UNDER THE ACT, OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. IN ADDITION, NO HEDGING
TRANSACTION MAY BE CONDUCTED WITH RESPECT TO THESE SECURITIES UNLESS SUCH
TRANSACTION IS IN COMPLIANCE WITH THE ACT.

                                MEDIBUY.COM, INC.

                           WARRANT TO PURCHASE 154,853 SHARES      NO: C-1

                                 OF COMMON STOCK

         THIS CERTIFIES THAT, for value received, Allianz Capital Partners, GMBH
is entitled to subscribe for and purchase one hundred fifty-four thousand eight
hundred fifty-three (154,853) shares of the fully paid and nonassessable Common
Stock (as adjusted pursuant to Section 4 hereof, the "Shares") of MEDIBUY.COM,
INC., a Delaware corporation (the "Company"), at the price of $0.30 per share
(such price and such other price as shall result, from time to time, from the
adjustments specified in Section 4 hereof is herein referred to as the "Warrant
Price"), subject to the provisions and upon the terms and conditions hereinafter
set forth. As used herein, the term "Date of Grant" shall mean January 7, 2000.

         1.       TERM; EXERCISABILITY.

                  (a) TERM. The purchase right represented by this Warrant is
exercisable, in whole or in part, at any time and from time to time from the
Effective Date (as defined in Section 1(b) below) through the second anniversary
of the Date of Grant; provided that the Warrant shall expire earlier upon the
Termination Date as defined under Section 1(c) below.

                  (b) EFFECTIVE DATE. No holder of this Warrant shall be
entitled to exercise this Warrant for all or any part of the Shares until the
occurrence of the earliest of (i) June 30, 2000, or the date on which the
Company's registration statement filed with the Securities and Exchange
Commission (the "SEC") under the Securities Act of 1933, as amended (the
"Securities Act"), (ii) in connection with the Company's initial public
offering, is declared effective by the SEC (the "Effective Date") or (iii) upon
a Reorganization Transaction (as defined below).

                                       1.
<PAGE>   2

                  (c) TERMINATION DATE. Notwithstanding anything herein to the
contrary, this Warrant shall expire and shall be wholly void and have no effect
after 5:00 p.m., San Diego, California time, on the date (the "Termination
Date") which is the earlier of (i) the thirtieth (30th) calendar day following
the date on which the Company gives notice to the holder of this Warrant that
the average closing price of the Company's Common Stock for the immediately
preceding sixty (60) trading days on the Nasdaq National Market or on any
securities exchange (or if the Common Stock is traded in an over-the-counter
market, the average of the closing ask prices over such period) equals or
exceeds $41.08 per share (such dollar amount per share to be adjusted
proportionately for any stock split, combination or similar event); provided,
that in the event the Shares are not tradeable under Rule 144 under the
Securities Act, or covered by an effective registration statement under the
Securities Act on such Termination Date, then the Termination Date shall be
extended for purposes of this Section 1(c)(i) until the tenth (10th) day
following the first to occur of (A) the date on which the Shares may be sold
pursuant to Rule 144 under the Securities Act or the effective date of a
registration statement covering the resale of the Shares under the Securities
Act; or (ii) the closing date of a Reorganization Transaction (the first to
occur of such dates being hereinafter referred to as the "Termination Date").
For purposes of this Warrant, any of the following shall constitute a
"Reorganization Transaction": a merger or consolidation of the Company with or
into another corporation in which the Company is not the surviving entity, or a
reverse triangular merger in which the Company is the surviving entity but the
shares of the Company's capital stock outstanding immediately prior to the
merger are converted by virtue of the merger into other property, whether in the
form of securities, cash, or otherwise, or any other similar transaction in
which the holders of voting power of the Company immediately prior to such
transaction hold less than a majority of the surviving or resulting entity
immediately following such transaction. The Company shall give the holder of
this Warrant notice of a Reorganization Transaction at least 20 calendar days
prior to the closing of such Reorganization Transaction.

         2. METHOD OF EXERCISE; PAYMENT; ISSUANCE OF NEW WARRANT. Subject to
Section 1 hereof, the purchase right represented by this Warrant may be
exercised by the holder hereof in whole or in part by the surrender of this
Warrant (with the notice of exercise form attached hereto as Exhibit A, or if
the Warrant is exercised pursuant to the net issuance provisions of Section 9
with the notice of exercise form attached hereto as Exhibit A-1, duly executed)
at the principal office of the Company and, if applicable, by the payment to the
Company, by check, of an amount equal to the then applicable Warrant Price
multiplied by the number of Shares then being purchased. The person or persons
in whose name(s) any certificate(s) representing shares of Common Stock shall be
issuable upon exercise of this Warrant shall be deemed to have become the
holder(s) of record of, and shall be treated for all purposes as the record
holder(s) of, the shares represented thereby (and such shares shall be deemed to
have been issued) immediately prior to the close of business on the date or
dates upon which this Warrant is exercised. In the event of any exercise of the
rights represented by this Warrant, certificates for the shares of stock so
purchased shall be delivered to the holder hereof as soon as possible and in any
event within fifteen (15) calendar days after such exercise (except that if the
Company's Common Stock is then publicly traded, such certificates shall be
delivered within three (3) business days) and, unless this Warrant has been
fully exercised or expired, a new Warrant representing the portion of the
Shares, if any, with respect to which this Warrant shall not then have been
exercised shall also be issued to the holder hereof as soon as possible and in
any event within such fifteen (15) day period.

                                       2.
<PAGE>   3

         3. STOCK FULLY PAID; RESERVATION OF SHARES. All Shares that may be
issued upon the exercise of the rights represented by this Warrant will, upon
issuance pursuant to the terms and conditions herein, be fully paid and
nonassessable, and free from all taxes, liens and charges with respect to the
issue thereof. During the period within which the rights represented by this
Warrant may be exercised, the Company will at all times have authorized, and
reserved for the purpose of the issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Common Stock to
provide for the exercise of the rights represented by this Warrant.

         4. ADJUSTMENT OF WARRANT PRICE AND NUMBER OF SHARES. The number and
kind of securities purchasable upon the exercise of this Warrant and the Warrant
Price shall be subject to adjustment from time to time upon the occurrence of
certain events, as follows:

                  (a) RECLASSIFICATION, ETC. If the Company, at any time while
this Warrant, or any portion hereof, remains outstanding and unexpired by
reclassification of securities or otherwise, shall change any of the securities
as to which purchase rights under this Warrant exist into the same or a
different number of securities of any other class or classes, this Warrant shall
thereafter represent the right to acquire such number and kind of securities as
would have been issuable as the result of such change with respect to the
securities that were subject to the purchase rights under this Warrant
immediately prior to such reclassification or other change and the Warrant Price
therefor shall be appropriately adjusted, all subject to further adjustment as
provided in this Section 4.

                  (b) SPLIT, SUBDIVISION OR COMBINATION OF SHARES. If the
Company at any time while this Warrant, or any portion hereof, remains
outstanding and unexpired shall split, subdivide or combine the securities as to
which purchase rights under this Warrant exist, into a different number of
securities as to which purchase rights under this Warrant exist, or into a
different number of securities of the same class, the number of shares of Common
Stock purchasable upon exercise immediately prior to such action shall be
adjusted so that the holder shall be entitled to receive the kind and number of
shares of Common Stock or other securities of the Company which it would have
owned or would have been entitled to receive immediately after such action had
the Warrant been exercised immediately prior to such action and the Warrant
Price shall be appropriately adjusted, all subject to further adjustment as
provided in this Section 4.

                  (c) ADJUSTMENTS FOR DIVIDENDS IN STOCK OR OTHER SECURITIES OR
PROPERTY. If while this Warrant, or any portion hereof, remains outstanding and
unexpired, the holders of the securities as to which purchase rights under this
Warrant exist at the time shall have received, or, on or after the record date
fixed for the determination of eligible stockholders, shall have become entitled
to receive, without payment therefor, other or additional stock or other
securities or property (other than cash) of the Company by way of dividend, then
and in each case, this Warrant shall represent the right to acquire, in addition
to the number of shares of the security receivable upon exercise of this
Warrant, and without payment of any additional consideration therefor, the
amount of such other or additional stock or other securities or property (other
than cash) of the Company that such holder would have been entitled to receive
immediately after such action had the Warrant been so exercised immediately
prior to such action, and the Warrant Price shall be appropriately reduced, all
subject to further adjustment as provided in this Section 4.

                                       3.
<PAGE>   4

                  (d) ADJUSTMENTS FOR EXTRAORDINARY CASH DIVIDENDS OR
DISTRIBUTIONS. If while this Warrant, or any portion hereof, remains outstanding
and unexpired, but is not yet exercisable, the Company determines to make any
extraordinary cash dividends or distributions to its stockholders, including in
liquidation, then the appropriate adjustment (as determined in good faith by the
Board of Directors) shall be made in the application of the provisions of this
Warrant with respect to the rights of the holder after the transaction to the
end that the holder would be entitled to receive immediately after the
transaction such securities or other property as such holder would have been
entitled to receive had the Warrant been exercised immediately prior to such
action, with the Warrant Price appropriately adjusted, all subject to further
adjustment as provided in this Section 4.

         5. NOTICE OF ADJUSTMENTS. Whenever the Warrant Price or the number of
Shares purchasable hereunder shall be adjusted pursuant to Section 4 hereof, the
Company shall make a certificate signed by its chief financial officer setting
forth, in reasonable detail, the event requiring the adjustment, the amount of
the adjustment, the method by which such adjustment was calculated, and the
Warrant Price and the number of Shares purchasable hereunder after giving effect
to such adjustment, which shall be mailed to the holder of this Warrant in
accordance with Section 12 of this Warrant.

         6. FRACTIONAL SHARES. No fractional shares of Common Stock will be
issued in connection with any exercise hereunder, but in lieu of such fractional
shares the Company shall make a cash payment therefor based on the fair market
value of the Common Stock on the date of exercise as reasonably determined in
good faith by the Company's Board of Directors.

         7. COMPLIANCE WITH SECURITIES ACT; DISPOSITION OF WARRANT OR SHARES.

                  (a) COMPLIANCE WITH SECURITIES ACT. The holder of this
Warrant, by acceptance hereof, agrees that this Warrant, and the shares of
Common Stock to be issued upon exercise hereof are being acquired for investment
and that such holder will not offer, sell or otherwise dispose of this Warrant,
or any shares of Common Stock to be issued upon exercise hereof except under
circumstances which will not result in a violation of the Securities Act. Upon
exercise of this Warrant, unless the Shares being acquired are registered under
the Securities Act or an exemption from such registration is available, the
holder hereof shall confirm in writing, by executing the form attached as
Schedule 1 to Exhibit A and Exhibit A-1 hereto, that the shares of Common Stock
so purchased are being acquired for investment and not with a view toward
distribution or resale. This Warrant and all shares of Common Stock issued upon
exercise of this Warrant (unless registered under the Securities Act) shall be
stamped or imprinted with a legend in substantially the following forms:

         "THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
         SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES
         LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE
         REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL FOR
         THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH
         REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM
         THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING
         WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER

                                       4.
<PAGE>   5

         WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY."

         "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
         PURSUANT TO REGULATION S OF THE ACT, AND MAY NOT BE SOLD, MORTGAGED,
         PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
         WITH REGULATION S, PURSUANT TO A REGISTRATION UNDER THE ACT, OR
         PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. THE ISSUER OF
         THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND
         SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY
         PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY
         APPLICABLE STATE SECURITIES LAWS. IN ADDITION, NO HEDGING TRANSACTION
         MAY BE CONDUCTED WITH RESPECT TO THESE SECURITIES UNLESS SUCH
         TRANSACTION IS IN COMPLIANCE WITH THE ACT."

         In addition, in connection with the issuance of this Warrant, the
holder specifically represents to the Company by acceptance of this Warrant as
follows:

                              (i) The holder is aware of the Company's business
affairs and financial condition, and has acquired information about the Company
sufficient to reach an informed and knowledgeable decision to acquire this
Warrant. The holder is acquiring this Warrant for its own account for investment
purposes only and not with a view to, or for the resale in connection with, any
"distribution" thereof for purposes of the Securities Act.

                           (ii) The holder understands that this Warrant has not
been registered under the Securities Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide
nature of the holder's investment intent as expressed herein. In this
connection, the holder understands that, in the view of the SEC, the statutory
basis for such exemption may be unavailable if the holder's representation was
predicated solely upon a present intention to hold the Warrant for the minimum
capital gains period specified under tax statutes, for a deferred sale, for or
until an increase or decrease in the market price of the Warrant, or for a
period of one year or any other fixed period in the future.

                           (iii) The holder further understands that this
Warrant must be held indefinitely unless subsequently registered under the
Securities Act and any applicable state securities laws, or unless exemptions
from registration are otherwise available. Moreover, the holder understands that
the Company is under no obligation to register this Warrant.

                           (iv) The holder is aware of the provisions of Rule
144 and 144A, promulgated under the Securities Act, which, in substance, permit
limited public resale of "restricted securities" acquired, directly or
indirectly, from the issuer thereof (or from an affiliate of such issuer), in a
non-public offering subject to the satisfaction of certain conditions, if
applicable, including, among other things: the availability of certain public
information about the Company, the resale occurring not less than one year after
the party has purchased and paid for the securities to be sold; the sale being
made through a broker in an unsolicited "broker's transaction" or in
transactions directly with a market maker (as said term is defined under the

                                       5.
<PAGE>   6

Securities Exchange Act of 1934, as amended) and the amount of securities being
sold during any three-month period not exceeding the specified limitations
stated therein.

                              (v) The holder further understands that at the
time it wishes to sell this Warrant there may be no public market upon which to
make such a sale, and that, even if such a public market then exists, the
Company may not be satisfying the current public information requirements of
Rule 144 and 144A, and that, in such event, the holder may be precluded from
selling this Warrant under Rule 144 and 144A even if the one-year minimum
holding period had been satisfied.

                              (vi) The holder further understands that in the
event all of the requirements of Rule 144 and 144A are not satisfied,
registration under the Securities Act or another registration exemption will be
required; and that, not withstanding the fact that Rule 144 and 144A are not
exclusive, the Staff of the SEC has expressed its opinion that persons proposing
to sell private placement securities other than in a registered offering and
otherwise than pursuant to Rule 144 and 144A will have a substantial burden of
proof in establishing that an exemption from registration is available for such
offers or sales, and that such persons and their respective brokers who
participate in such transactions do so at their own risk.

                  (b) DISPOSITION OF WARRANT OR SHARES. With respect to any
offer, sale or other disposition of this Warrant or any shares of Common Stock
acquired pursuant to the exercise of this Warrant prior to registration of such
Warrant or shares, the holder hereof and each subsequent holder of this Warrant
agrees to give written notice to the Company prior thereto, describing briefly
the manner thereof, together with a written opinion of such holder's counsel, if
reasonably requested by the Company, to the effect that such offer, sale or
other disposition may be effected without registration or qualification (under
the Securities Act as then in effect or any federal or state law then in effect)
of this Warrant or such shares of Common Stock and indicating whether or not
under the Securities Act certificates for this Warrant or such shares of Common
Stock to be sold or otherwise disposed of require any restrictive legend as to
applicable restrictions on transferability in order to ensure compliance with
such law. Promptly upon receiving such written notice and reasonably
satisfactory opinion, if so requested, the Company, as promptly as practicable,
shall notify such holder that such holder may sell or otherwise dispose of this
Warrant or such shares of Common Stock, all in accordance with the terms of the
notice delivered to the Company. If a determination has been made pursuant to
this subsection (b) that the opinion of counsel for the holder is not reasonably
satisfactory to the Company, the Company shall so notify the holder promptly
after such determination has been made and shall specify in detail the legal
analysis supporting any such conclusion. Notwithstanding the foregoing, this
Warrant or such shares of Common Stock may, as to such federal laws, be offered,
sold or otherwise disposed of in accordance with Rule 144 or 144A under the
Securities Act, provided that the Company shall have been furnished with such
information as the Company may reasonably request to provide a reasonable
assurance that the provisions of Rule 144 or 144A have been satisfied. Each
certificate representing this Warrant or the shares of Common Stock thus
transferred (except a transfer pursuant to Rule 144 or 144A) shall bear a legend
as to the applicable restrictions on transferability in order to ensure
compliance with such laws, unless in the aforesaid opinion of counsel for the
holder, such legend is not required in order to ensure compliance with such
laws. The Company may issue stop transfer instructions to its transfer agent in
connection with such restrictions.

                                       6.
<PAGE>   7

                  (c) EXCEPTED TRANSFERS. Neither any restrictions of any legend
described in this Warrant nor the requirements of Section 7(b) above shall apply
to any transfer without any additional consideration of, or grant of a security
interest in, this Warrant or any part hereof (i) to a partner of the holder if
the holder is a partnership, (ii) by the holder to a partnership of which the
holder is a general partner, or (iii) to any affiliate of the holder if the
holder is a corporation; provided, however, in any such transfer, the transferee
shall on the Company's request agree in writing to be bound by the terms of this
Warrant as if an original signatory hereto.

                  (d) "MARKET STAND-OFF" AGREEMENT. Notwithstanding anything
herein to the contrary, if requested by the Company and an underwriter of Common
Stock (or other securities) of the Company, no holder shall sell or otherwise
transfer or dispose of any Shares (or other securities) of the Company then
owned by such holder (other than those that may be included in the registration,
if any) during the one hundred eighty (180) day period (or such lesser period as
is permitted by the underwriter) following the Effective Date, provided that:

                  (a) such agreement shall only apply to the first such
registration statement of the Company which covers securities to be sold on its
behalf to the public in an underwritten offering; and

                  (b) all officers and directors of the Company then holding
securities of the Company are bound by and have entered into similar agreements.

         The obligations described in this Section 7(d) shall not apply to a
registration relating solely to employee benefit plans on Form S-1 or Form S-8
or similar forms that may be promulgated in the future, or a registration
relating solely to an SEC Rule 145 transaction on Form S-4 or similar forms that
may be promulgated in the future. In order to enforce the above covenant, the
Company shall have the right to place restrictive legends on the certificates
representing the Shares subject to this Section 7(d) and to impose stop-transfer
instructions with respect to the securities subject to the foregoing restriction
until the end of such one hundred eighty (180) day period.

         8. RIGHTS AS STOCKHOLDERS; INFORMATION. Except only as otherwise
provided under Section 4(c) of this Warrant, no holder of this Warrant, as such,
shall be entitled to vote or receive dividends or be deemed the holder of Common
Stock or any other securities of the Company which may at any time be issuable
on the exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon the holder of this Warrant, as such, any of the rights
of a stockholder of the Company or any right to vote for the election of
directors or upon any matter submitted to stockholders at any meeting thereof,
or to receive notice of meetings, or to receive dividends or subscription rights
or otherwise until this Warrant shall have been exercised and the Shares
purchasable upon the exercise hereof shall have become deliverable, as provided
herein.

         9.       RIGHT TO CONVERT WARRANT INTO COMMON STOCK; NET ISSUANCE.

                  (a) RIGHT TO CONVERT. In addition to and without limiting the
rights of the holder under the terms of this Warrant, the holder shall have the
right to convert this Warrant or any portion thereof (the "Conversion Right")
into shares of Common Stock as provided in this Section 9 at any time or from
time to time during the term of this Warrant. Upon exercise of the Conversion
Right with respect to a particular number of shares subject to this Warrant (the

                                       7.
<PAGE>   8

"Converted Warrant Shares"), the Company shall deliver to the holder (without
payment by the holder of any exercise price or any cash or other consideration)
(X) that number of shares of fully paid and nonassessable Common Stock equal to
the quotient obtained by dividing the value of this Warrant (or the specified
portion hereof) on the Conversion Date (as defined in subsection (b) hereof),
which value shall be determined by subtracting (A) the aggregate Warrant Price
of the Converted Warrant Shares immediately prior to the exercise of the
Conversion Right from (B) the aggregate fair market value of the Converted
Warrant Shares issuable upon exercise of this Warrant (or the specified portion
hereof) on the Conversion Date (as herein defined), by (Y) the fair market value
of one share of Common Stock on the Conversion Date (as herein defined).

Expressed as a formula, such conversion shall be computed as follows:

X=B-A
  ---
   Y

Where:   X = the number of shares of Common Stock that may be issued to holder

         Y = the fair market value (FMV) of one share of Common Stock

         A = the aggregate Warrant Price (i.e., Converted Warrant Shares x
             Warrant Price)

         B = the aggregate FMV (i.e., FMV x Converted Warrant Shares)

         No fractional shares shall be issuable upon exercise of the Conversion
Right, and, if the number of shares to be issued determined in accordance with
the foregoing formula is other than a whole number, the Company shall pay to the
holder an amount in cash equal to the fair market value of the resulting
fractional share on the Conversion Date (as hereinafter defined).

                  (b) METHOD OF EXERCISE. The Conversion Right may be exercised
by the holder by the surrender of this Warrant at the principal office of the
Company together with a notice of exercise substantially in the form attached
hereto as Exhibit A-1, specifying that the holder thereby intends to exercise
the Conversion Right and indicating the number of shares subject to this Warrant
that are being surrendered (referred to in subsection (a) hereof as the
Converted Warrant Shares) in exercise of the Conversion Right. Such conversion
shall be effective upon receipt by the Company of this Warrant together with the
aforesaid notice of exercise, or on such later date as is specified therein (the
"Conversion Date"). Certificates for the shares issuable upon exercise of the
Conversion Right and, if applicable, a new warrant evidencing the balance of the
shares remaining subject to this Warrant, shall be issued as of the Conversion
Date and shall be delivered to the holder within fifteen (15) calendar days
following the Conversion Date (except that if the Company's Common Stock is then
publicly traded, such certificates shall be delivered within three (3) business
days following the Conversion Date).

                  (c) DETERMINATION OF FAIR MARKET VALUE. For purposes of this
Section 9, "fair market value" of a share of Common Stock as of a particular
date (the "Determination Date") shall mean:

                              (i) If traded on a securities exchange or the
Nasdaq National Market, the fair market value of the Common Stock shall be
deemed to be the average of the closing or

                                       8.
<PAGE>   9

last reported sale prices of the Common Stock on such exchange or market over
the ten (10) calendar day period ending five business days prior to the
Determination Date;

                              (ii) If otherwise traded in an over-the-counter
market, the fair market value of the Common Stock shall be deemed to be the
average of the closing ask prices of the Common Stock over the ten (10) calendar
day period ending five business days prior to the Determination Date;

                              (iii) If there is no public market for the Common
Stock, then fair market value shall be determined by mutual agreement of the
holder of this Warrant and the Company, and if the holder and the Company are
unable to so agree, at the Company's sole expense by an investment banker of
national reputation selected by the Company and reasonably acceptable to the
holder of this Warrant.

         10. REPRESENTATIONS AND WARRANTIES. The Company represents and warrants
to the holder of this Warrant as follows:

                  (a) This Warrant has been duly authorized and executed by the
Company and is a valid and binding obligation of the Company enforceable in
accordance with its terms, subject to laws of general application relating to
bankruptcy, insolvency and the relief of debtors and the rules of law or
principles at equity governing specific performance, injunctive relief and other
equitable remedies.

                  (b) The Shares have been duly authorized and reserved for
issuance by the Company and, when issued in accordance with the terms hereof,
will be validly issued, fully paid and nonassessable.

                  (c) The execution and delivery of this Warrant are not, and
the grant of the right to acquire the Shares upon exercise of this Warrant in
accordance with the terms hereof is not inconsistent with the Company's
certificate of incorporation or bylaws, and do not contravene any law,
governmental rule or regulation, judgment or order applicable to the Company,
and do not conflict with or contravene any provision of, or constitute a default
under, any indenture, mortgage, contract or other instrument of which the
Company is a party or by which it is bound or require the consent or approval
of, the giving of notice to, the registration or filing with or the taking of
any action in respect of or by, any Federal, state or local government authority
or agency or other person, except for the filing of notices pursuant to federal
and state securities laws, which filings will be effected by the time required
thereby.

                  (d) There currently are no actions, suits, audits,
investigations or proceedings pending or, to the knowledge of the Company,
threatened against the Company in any court or before any governmental
commission, board or authority which, if adversely determined, will have a
material adverse effect on the ability of the Company to perform its obligations
under this Warrant.

         11. MODIFICATION AND WAIVER. This Warrant and any provision hereof may
be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of the same is sought.

                                       9.
<PAGE>   10

         12. NOTICES. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the
party to be notified, (b) when sent by confirmed telex or facsimile if sent
during normal business hours of the recipient, if not, then on the next business
day, (c) ten (10) days after having been sent by registered or certified mail,
return receipt requested, postage prepaid, or (d) four (4) business days after
deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent
to the holder at its address as shown on the books of the Company and to the
Company at the address indicated therefor on the signature page of this Warrant.

         13. BINDING EFFECT ON SUCCESSORS. This Warrant shall be binding upon
any corporation succeeding the Company by merger, consolidation or acquisition
of all or substantially all of the Company's assets, and all of the covenants
and agreements of the Company hereunder shall inure to the benefit of the
successors and assigns of the holder hereof. The Company will, at the time of
the exercise or conversion of this Warrant, in whole or in part, upon request of
the holder hereof but at the Company's expense, acknowledge in writing its
continuing obligation to the holder hereof in respect of any such rights.

         14. LOST WARRANTS OR STOCK CERTIFICATES. The Company covenants to the
holder hereof that, upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant or any
stock certificate representing any Shares and, in the case of any such loss,
theft or destruction, upon receipt of an indemnity reasonably satisfactory to
the Company, or in the case of any such mutilation upon surrender and
cancellation of such Warrant or stock certificate representing any Shares, the
Company will make and deliver a new Warrant or stock certificate, of like tenor,
in lieu of the lost, stolen, destroyed or mutilated Warrant or stock
certificate.

         15. DESCRIPTIVE HEADINGS. The descriptive headings of the several
paragraphs of this Warrant are inserted for convenience only and do not
constitute a part of this Warrant.

         16. GOVERNING LAW. This Warrant shall be construed and enforced in
accordance with, and the rights of the parties shall be governed by, the laws of
the State of California.

         17. SURVIVAL OF REPRESENTATIONS WARRANTIES AND AGREEMENTS. All
representations and warranties of the Company and the holder hereof contained
herein shall survive the Date of Grant, the exercise or conversion of this
Warrant (or any part hereof) or the termination or expiration of rights
hereunder. All agreements of the Company and the holder hereof contained herein
shall survive indefinitely until, by their respective terms, they are no longer
operative.

         18. REMEDIES. In case any one or more of the covenants and agreements
contained in this Warrant shall have been breached, the holder hereof (in the
case of a breach by the Company), or the Company (in the case of a breach by a
holder), may proceed to protect and enforce their or its rights either by suit
in equity and/or by action at law, including, but not limited to, an action for
damages as a result of any such breach and/or an action for specific performance
of any such covenant or agreement contained in this Warrant.

         19. ACCEPTANCE. Receipt of this Warrant by the holder hereof shall
constitute acceptance of and agreement to the foregoing terms and conditions.

                                      10.
<PAGE>   11

         20. NO IMPAIRMENT OF RIGHTS. The Company will not, by amendment of its
certificate of incorporation or through any other means, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant, but will at
all times in good faith assist in the carrying out of all such terms and in the
taking of all such action as may be necessary or appropriate in order to protect
the rights of the holder of this Warrant against impairment.

                                      11.
<PAGE>   12

         IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its officer thereunto as of the date set forth below.

                                   MEDIBUY.COM, INC.

                                   By:
                                       --------------------------------------
                                       Name:
                                       Title:
                                       Address:  10120 Pacific Heights Blvd.,
                                                 Suite 100
                                                 San Diego, CA  92121

Date: January ___, 2000

                                      12.
<PAGE>   13

                                    EXHIBIT A

                               NOTICE OF EXERCISE

To:  MEDIBUY.COM, INC.

         1. The undersigned hereby elects to purchase _____________ shares of
Common Stock of MEDIBUY.COM, INC. pursuant to the terms of the attached Warrant,
and tenders herewith payment of the purchase price of such shares in full.

         2. Please issue a certificate or certificates representing said shares
in the name of the undersigned or in such other name or names as are specified
below:

                        -------------------------------------
                                     (Name)

                        -------------------------------------

                        -------------------------------------
                                    (Address)

         3. The undersigned represents that the aforesaid shares are being
acquired for the account of the undersigned for investment and not with a view
to, or for resale in connection with, the distribution thereof and that the
undersigned has no present intention of distributing or reselling such shares.
In support thereof and if required under Section 7(a) of the Warrant, the
undersigned has executed an Investment Representation Statement attached hereto
as Schedule 1.

                        -------------------------------------
                                   (Signature)

-------------------------------------
               (Date)

<PAGE>   14

                                   EXHIBIT A-1

              NOTICE OF EXERCISE OF NET ISSUANCE CONVERSION RIGHTS

To:      MEDIBUY.COM, INC.

         1. The undersigned, the registered holder of the Warrant delivered
herewith (the "Warrant"), hereby elects to exercise the Conversion Right (as
defined in Section 9 of the Warrant) as provided herein. ___________ shares
subject to the Warrant are being surrendered hereby in exercise of the
Conversion Right. The number of shares to be issued pursuant to this exercise
shall be determined by reference to the formula in Section 9(a) of the Warrant,
which requires the use of the "fair market value" of the Company's stock. As of
the Determination Date (as defined in the Warrant), the "fair market value" of
one share of Common Stock shall be determined in the manner provided in Section
9(c) of the Warrant, which amount has been determined by the undersigned (or
agreed to by the holder of the Warrant and medibuy.com, Inc.) to be
$_____________ per share. Therefore, ____________ shares are to be issued to the
undersigned pursuant to this exercise.

         2. Please issue a certificate or certificates representing said shares
in the name of the undersigned or in such other name or names as are specified
below:

                        -------------------------------------
                                     (Name)

                        -------------------------------------

                        -------------------------------------
                                    (Address)

         3. The undersigned represents that the aforesaid shares are being
acquired for the account of the undersigned for investment and not with a view
to, or for resale in connection with, the distribution thereof and that the
undersigned has no present intention of distributing or reselling such shares.
In support thereof and if required under Section 7(a) of the Warrant, the
undersigned has executed an Investment Representation Statement attached hereto
as Schedule 1.

                        -------------------------------------
                                   (Signature)

-------------------------------------
               (Date)

<PAGE>   15

                                   SCHEDULE 1

                       INVESTMENT REPRESENTATION STATEMENT

Purchaser:
          ----------------------------------
Company:       MEDIBUY.COM, INC.

Security:      Common Stock

Amount:
        -------------------------------------
Date:
        -------------------------------------

         In connection with the purchase of the above-listed securities (the
"Securities"), the undersigned (the "Purchaser") represents to the Company as
follows:

         (a) The Purchaser is aware of the Company's business affairs and
financial condition, and has acquired sufficient information about the Company
to reach an informed and knowledgeable derision to acquire the Securities. The
Purchaser is purchasing the Securities for its own account for investment
purposes only and not with a view to, or for the resale in connection with, any
"distribution" thereof for purposes of the Securities Act of 1933, as amended
(the "Act").

         (b) The Purchaser understands that the Securities have not been
registered under the Act in reliance upon a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of the
Purchaser's investment intent as expressed herein. In this connection, the
Purchaser understands that, in the view of the Securities and Exchange
Commission ("SEC"), the statutory basis for such exemption may be unavailable if
the Purchaser's representation was predicated solely upon a present intention to
hold these Securities for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the
market price of the Securities, or for a period of one year or any other fixed
period in the future.

         (c) The Purchaser further understands that the Securities must be held
indefinitely unless subsequently registered under the Act or unless an exemption
from registration is otherwise available. Moreover, the Purchaser understands
that the Company is under no obligation to register the Securities except as set
forth in the Warrant under which the Securities are being acquired. In addition,
the Purchaser understands that the certificate evidencing the Securities will be
imprinted with the legend referred to in the Warrant under which the Securities
are being purchased.

         (d) The Purchaser is aware of the provisions of Rule 144 and 144A,
promulgated under the Act, which, in substance, permit limited public resale of
"restricted securities" acquired, directly or indirectly, from the issuer
thereof (or from an affiliate of such issuer), in a non-public offering subject
to the satisfaction of certain conditions, if applicable, including, among other
things: the availability of certain public information about the Company; the
resale occurring not less than one year after the party has purchased and paid
for the securities to be

<PAGE>   16

sold; the sale being made through a broker in an unsolicited "broker's
transaction" or in transactions directly with a market maker (as said term is
defined under the Securities Exchange Act of 1934, as amended); and the amount
of securities being sold during any three-month period not exceeding the
specified limitations stated therein.

         (e) The Purchaser further understands that at the time it wishes to
sell the Securities there may be no public market upon which to make such a
sale, and that, even if such a public market then exists, the Company may not be
satisfying the current public information requirements of Rule 144 and 144A, and
that, in such event, the Purchaser may be precluded from selling the Securities
under Rule 144 and 144A even if the two-year minimum holding period had been
satisfied.

         (f) The Purchaser further understands that in the event all of the
requirements of Rule 144 and 144A are not satisfied, registration under the Act
or another registration exemption will be required; and that, notwithstanding
the fact that Rule 144 is not exclusive, the Staff of the SEC has expressed its
opinion that persons proposing to sell private placement securities other than
in a registered offering and otherwise than pursuant to Rule 144 will have a
substantial burden of proof in establishing that an exemption from registration
is available for such offers or sales, and that such persons and their
respective brokers who participate in such transactions do so at their own risk.

                                                Purchaser:

                                                ------------------------

                                                Date:__________, 200__

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00000-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00000-of-00352.parquet"}]]